Diacylglycerol acyltransferase inhibitors
Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity, type II diabetes mellitus and metabolic syndrome.
1. A compound of the formula (I):
wherein:
R 1 is phenyl or phenyl substituted with a group selected from the group consisting of alkyl, —O-alkyl, haloalkoxy, methoxy-ethoxy, halogen, or cycloalkyl containing 4 to 7 carbon atoms;
R 2 is C;
R 3 is N;
R 4 is S or O;
R 5 is C;
R 6 is H, alkyl, halogen, haloalkyl, or thioalkyl;
R 7 is
wherein one of R 8 and R 9 is nitrogen and the other is carbon;
R 10 is —NR 11 R 12 , O-alkyl, hydroxy-dimethylethylamino, hydroxyl-methylethylamino, cyclohept-2-ylamino, morpholino, thiomorpholino, oxothiomorpholino, dioxothiomorpholino, alkyl-carbamoyl-alkyl-amino, difluoroazetidine, ethoxyazetidine, or a 4- to 6-membered cyclic ring having from 1 to 3 hetero ring atoms selected from the group consisting of S, N and O substituted with a group selected from the group consisting of amino, —N(CH 3 )C(O)CH 3 , cyclopropanecarbonyl-methyl, —OCH 3 , —OCH 2 C(O)OC(CH 3 ) 3 , OCH 2 C(O)OH, —CH 2 OH, —CH 2 OCH 3 and —OH;
R 11 is H, lower alkyl, alkoxyalkyl, alkyl-aryl, trifluoromethyl, cyclopropylmethoxy-ethyl, —CH 2 CH 2 CN, hydroxyalkyl, cycloalkyl, or a 4- to 6-membered cyclic ring having from 1 to 3 hetero ring atoms selected from the group consisting of S, N and O, unsubstituted or substituted with a group selected from the group consisting of —OCH 3 , —CH 2 OH, —CH 2 OCH 3 , —OCH 2 C(O)OC(CH 3 ) 3 , —OCH 2 C(O)OH and —OH;
R 12 is H or lower alkyl;
or a pharmaceutically acceptable salt thereof.
2. The compound according to claim 1 wherein:
R 1 is unsubstituted phenyl or phenyl substituted with a group selected from the group consisting of alkyl and halogen.
3. The compound according to claim 1 wherein:
R 10 is —NR 11 R 12 ;
R 11 is H, lower alkyl, alkyl ether, alkyl alcohol, acyl or a 5- or 6-membered cyclic ring having from 1 to 3 hetero ring atoms selected from the group consisting of S, N and O, unsubstituted or substituted with a group selected from the group consisting of —OCH 3 , —CH 2 OH, —CH 2 OCH 3 and —OH;
R 12 is H or lower alkyl;
or a pharmaceutically acceptable salt thereof.
4. The compound according to claim 1 , wherein R 6 is —CF 3 .
5. The compound according to claim 1 wherein said compound has the formula:
wherein R 1 , R 6 , and R 10 have definitions as defined previously.
6. The compound according to claim 1 , wherein said compound is 2-phenyl-5-trifluoromethyl-oxazole-4-carboxylic acid [6-(ethyl-methyl-amino)-pyridin-3-yl]-amide.
7. The compound according to claim 1 , wherein said compound is 2-(2-chloro-phenyl)-4-propyl-oxazole-5-carboxylic acid {6-[(2-methoxy-ethyl)-methyl-amino]-pyridin-3-yl}-amide.
8. The compound according to claim 1 , wherein said compound is 2-phenyl-5-trifluoromethyl-oxazole-4-carboxylic acid [6-((S)-2-hydroxy-1-methyl-ethylamino)-pyridin-3-yl]-amide.
9. The compound according to claim 1 , wherein said compound is 2-phenyl-5-trifluoromethyl-oxazole-4-carboxylic acid {6-[(2-methoxy-ethyl)-methyl-amino]-pyridin-3-yl}-amide.
10. The compound according to claim 1 , wherein said compound is 2-(2-chloro-phenyl)-5-trifluoromethyl-oxazole-4-carboxylic acid {6-[(2-methoxy-ethyl)-methyl-amino]-pyridin-3-yl}-amide.
11. The compound according to claim 1 , wherein said compound is 2-phenyl-5-trifluoromethyl-oxazole-4-carboxylic acid (6-thiomorpholin-4-yl-pyridin-3-yl)-amide.